文献速递脊柱外科

新型抗菌植入物涂层预防脊柱植入物感染的体内研究

The Use of a Novel Antimicrobial Implant Coating In Vivo to Prevent Spinal Implant Infection.
PubMed 文献 · Spine (Phila Pa 1976) · 2020-01-01

本研究为对照性介入动物实验,在小鼠脊柱植入物感染模型中评估可降解PEG-PPS聚合物涂层递送万古霉素或替加环素的疗效。结果显示PEG-PPS-万古霉素涂层自术后第3天起显著降低感染负荷(P<0.05),且植入物及周围组织CFU低于替加环素涂层和单纯PEG-PPS组(P<0.05)。

要点

  • PEG-PPS-万古霉素涂层自术后第3天起显著降低感染负荷(P<0.05)。
  • PEG-PPS-替加环素涂层仅在术后第5至10天降低感染(P<0.05)。
  • 万古霉素涂层植入物及周围组织CFU均低于替加环素涂层和单纯PEG-PPS组(P<0.05)。

核心结论

  • 可降解PEG-PPS涂层在降低细菌负荷和预防脊柱植入物感染方面显示出应用前景。
  • 在本模型中万古霉素涂层优于替加环素涂层,与既往关节置换模型研究不同,凸显椎旁感染微环境的独特性。

研究设计与样本

  • 研究设计为对照性介入动物研究。
  • 采用既往建立的小鼠脊柱植入物感染模型,测试可降解PEG-PPS聚合物涂层递送万古霉素或替加环素的体内性能。
  • 使用无创生物发光成像定量细菌负荷,并通过植入物超声震荡确定植入物及周围骨与软组织的细菌菌落形成单位(CFUs)。

主要发现

  • PEG-PPS-万古霉素涂层自术后第3天起显著降低感染负荷(P<0.05),而PEG-PPS-替加环素涂层仅在术后第5至10天降低感染(P<0.05)。
  • 植入物CFU:PEG-PPS-万古霉素组2.4×10 vs PEG-PPS-替加环素组8.5×10 vs 单纯PEG-PPS组1.0×10(P<0.05)。
  • 周围骨与软组织CFU:PEG-PPS-万古霉素组1.3×10 vs PEG-PPS-替加环素组4.8×10 vs 单纯PEG-PPS组5.4×10(P<0.05)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY DESIGN: A controlled, interventional animal study. OBJECTIVE: Spinal implant infection (SII) is a devastating complication. The objective of this study was to evaluate the efficacy of a novel implant coating that has both a passive antibiotic elution and an active-release mechanism triggered in the presence of bacteria, using an in vivo mouse model of SII. SUMMARY OF BACKGROUND DATA: Current methods to minimize the frequency of SII include local antibiotic therapy (vancomycin powder), betadine irrigation, silver nanoparticles, and passive release from antibiotic-loaded poly(methyl methacrylate) cement beads, all of which have notable weaknesses. A novel implant coating has been developed to address some of these limitations but has not been tested in the environment of a SII. METHODS: A biodegradable coating using branched poly(ethylene glycol)-poly(propylene sulfide) (PEG-PPS) polymer was designed to deliver antibiotics. The in vivo performance of this coating was tested in the delivery of either vancomycin or tigecycline in a previously established mouse model of SII. Noninvasive bioluminescence imaging was used to quantify the bacterial burden, and implant sonication was used to determine bacterial colony-forming units (CFUs) from the implant and surrounding bone and soft tissue. RESULTS: The PEG-PPS-vancomycin coating significantly lowered the infection burden from postoperative day 3 onwards (P < 0.05), whereas PEG-PPS-tigecycline only decreased the infection on postoperative day 5 to 10 (P < 0.05). CFUs were lower on PEG-PPS-vancomycin pins than PEG-PPS-tigecycline and PEG-PPS pins alone on both the implants (2.4 × 10, 8.5 × 10, and 1.0 × 10 CFUs, respectively) and surrounding bone and soft tissue (1.3 × 10, 4.8 × 10, and 5.4 × 10 CFUs, respectively) (P < 0.05). CONCLUSION: The biodegradable PEG-PPS coating demonstrates promise in decreasing bacterial burden and preventing SII. The vancomycin coating outperformed the tigecycline coating in this model compared to prior work in arthroplasty models, highlighting the uniqueness of the paraspinal infection microenvironment. LEVEL OF EVIDENCE: N/A.

来源:Spine (Phila Pa 1976),查看原文。版权归原作者所有。

引用

  1. Hegde V, Park HY, Dworsky E, et al. The Use of a Novel Antimicrobial Implant Coating In Vivo to Prevent Spinal Implant Infection. Spine (Phila Pa 1976). 2020. PMID: 31593059. doi:10.1097/BRS.0000000000003279

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。